For instance, until recently, the mainstay of therapy for DKD highlighted metabolic and hemodynamic-related therapies via optimization of glucose and blood pressure control and the use of RAS inhibitors, namely ACE inhibitors and ARBs. Here, ACE is linked to diabetic kidney disease.